Welcome to our dedicated page for AbCellera Biologics Common Shares news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on AbCellera Biologics Common Shares stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a trailblazer in the Canadian biotechnology sector, specializing in the accelerated discovery of monoclonal antibody (mAbs) therapeutics. The company leverages cutting-edge microfluidic technology to address the complexities of identifying and developing effective antibodies from single immune cells. This breakthrough approach enables high-throughput analysis, expediting the process of bringing new therapies to patients who need them the most.
AbCellera's core business revolves around its integrated antibody discovery and development platform, which combines proprietary technologies, expert teams, and data-driven methodologies. This platform empowers AbCellera to identify and optimize clinical candidates with unparalleled speed and precision, offering a competitive edge to its partners. The company's strategic partnerships span emerging biotechs and leading pharmaceutical firms, aimed at tackling the most challenging issues in drug development.
Among its recent achievements, AbCellera presented groundbreaking data on its T-cell engager (TCE) programs at the Society for Immunotherapy of Cancer Annual Meeting. The innovative TCE platform includes novel CD3-binding antibodies engineered to fine-tune T-cell responses, thereby enhancing the efficacy and safety profiles of cancer therapies. AbCellera's research is breaking new ground in immuno-oncology, with promising results in targeting prostate-specific membrane antigen (PSMA) and melanoma-associated antigen 4 (MAGE-A4).
Financially, AbCellera reported $38 million in total revenue for 2023, alongside significant investments in research and development. Despite a net loss that reflects its aggressive growth strategy, the company remains well-positioned with approximately $1 billion in available liquidity. This financial stability supports continued innovation and expansion, particularly in advancing internal programs and strategic partnerships.
AbCellera is committed to overcoming traditional barriers in antibody drug discovery, aiming to deliver better medicines faster. The company's robust pipeline and forward-looking strategies make it a significant player in the biotech industry, poised to make a lasting impact on global healthcare.
AbCellera (Nasdaq: ABCL) announced a purchase agreement with the U.S. government, facilitating the supply of 614,000 doses of bamlanivimab with etesevimab for COVID-19 treatment, worth a total of $1.29 billion. Lilly will provide at least 400,000 doses by December 31, 2021. This therapy has reportedly treated over 535,000 patients, potentially preventing more than 25,000 hospitalizations and saving over 10,000 lives. Bamlanivimab is also part of AbCellera's broader efforts to combat COVID-19.
AbCellera (Nasdaq: ABCL) will release its third quarter 2021 financial results on November 9, 2021, followed by an earnings call at 2:00 p.m. PT (5:00 p.m. ET). The live conference can be accessed through AbCellera’s Investor Relations website, where a replay will also be available. AbCellera is a technology firm that aids in the discovery and development of antibodies for drug development by collaborating with a range of pharmaceutical and biotechnology partners.
AbCellera (Nasdaq: ABCL) has partnered with Everest Medicines Limited to discover therapeutic antibodies for up to 10 selected targets, primarily in oncology. This multi-year collaboration aims to enhance Everest's drug pipeline by leveraging AbCellera’s advanced antibody discovery technology, including humanized antibodies and bispecifics. Everest will develop and commercialize the resulting antibodies, while AbCellera will receive research payments and potential royalties. This partnership seeks to accelerate the delivery of innovative therapies to patients in Asia and beyond.
AbCellera (NASDAQ: ABCL) announced a Joint Procurement Agreement with the European Commission and Eli Lilly to supply up to 220,000 doses of bamlanivimab and etesevimab for COVID-19 treatment in Europe. This agreement allows EU/EEA countries to directly purchase these treatments after national approval. The two drugs effectively neutralize the highly contagious Delta variant, responsible for over 95% of new COVID-19 cases in the region. Bamlanivimab has already treated over 535,000 patients in the U.S., potentially preventing 25,000 hospitalizations.
AbCellera (Nasdaq: ABCL) has received expanded Emergency Use Authorization (EUA) from the FDA for bamlanivimab and etesevimab to include post-exposure prophylaxis against COVID-19. This update allows use among individuals at high risk who have been exposed to the virus. The authorization is based on Phase 3 trial results indicating up to an 80% reduction in COVID-19 risk in nursing home residents. Over 535,000 patients have been treated with these antibodies since their initial authorization.
AbCellera (Nasdaq: ABCL) announced a multi-year collaboration with Moderna to utilize its AI-powered antibody discovery platform alongside Moderna’s mRNA technology. This partnership aims to accelerate the development of mRNA-encoded antibody therapeutics for up to six targets. Moderna will hold the rights to develop and commercialize the antibodies, while AbCellera will receive research payments and potential milestone payments and royalties. CEO Carl Hansen emphasized the collaboration as a significant step in advancing genetic medicines.
AbCellera (Nasdaq: ABCL) has acquired TetraGenetics, enhancing its capabilities in antibody discovery for challenging transmembrane proteins. This all-cash transaction includes an upfront payment and potential milestone payments based on the successful development of therapeutics. TetraGenetics specializes in producing complex transmembrane proteins, crucial for developing antibodies against significant drug targets. The integration of these technologies is expected to empower AbCellera's therapeutic discovery efforts.
AbCellera (Nasdaq: ABCL) announced its participation in the BofA Securities – Tech Solutions for Drug Discovery Conference on September 20, 2021, at 9:00 a.m. Pacific Time. Executives from AbCellera will present virtually, with a live audio webcast accessible through the company's Investor Relations website. A replay will be available post-presentation. AbCellera specializes in antibody discovery to assist drug developers in combating diseases.
AbCellera (ABCL) reported Q2 2021 revenue of $27.6 million, a significant increase from $11.2 million in Q2 2020, driven by royalties from bamlanivimab. The company incurred a net loss of $2.3 million, contrasting with $6.7 million net earnings in the same quarter last year. AbCellera added 19 new programs, bringing its total to 138 under contract. Despite ongoing investments increasing R&D expenses to $15 million, the company aims to strengthen its pipeline through partnerships, including advancing two COVID-19 therapeutic antibodies.
EQRx and AbCellera have announced a collaboration to discover and develop therapeutic antibodies using AbCellera's AI-powered technology. This partnership aims to enhance EQRx’s early-stage pipeline, focusing on oncology and immunology. The collaboration includes an option for AbCellera to invest further at various development stages for a larger share of product sales. This agreement marks a significant step for EQRx in delivering affordable medicines.
FAQ
What is the current stock price of AbCellera Biologics Common Shares (ABCL)?
What is the market cap of AbCellera Biologics Common Shares (ABCL)?
What does AbCellera Biologics Inc. specialize in?
What is unique about AbCellera's technology?
What are T-cell engagers (TCEs) and why are they significant?
How does AbCellera collaborate with other companies?
What recent achievements has AbCellera made?
What is AbCellera's financial outlook?
Can you describe AbCellera's business model?
What are the therapeutic areas AbCellera focuses on?
How does AbCellera's technology benefit its partners?